The National Agency for Food and Drug Administration and Control has dismissed claims circulating on social media that Camosunate, an antimalarial medicine, has been banned in Nigeria.
The agency said it had never banned Camosunate or medicines containing the artesunate-amodiaquine combination, urging members of the public to disregard the reports.
NAFDAC made the clarification in a press release on Saturday which was signed by its Director-General, Prof. Mojisola Adeyeye.
“The Agency clarifies that it has never banned Camosunate or medicines containing the artesunate-amodiaquine combination,” the statement read.
It explained that some of the symptoms mentioned in the viral claims could be associated with known side effects of the medicine.
“Some of the symptoms reported in the viral claim may be associated with known side effects of Camosunate, including nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness, drowsiness and loss of appetite,” it stated.
However, the agency said suspected adverse drug reactions should be reported for proper assessment rather than being circulated as claims of a ban.
“However, suspected adverse drug reactions should be reported to NAFDAC for proper assessment,” it added.
The regulatory agency encouraged members of the public and healthcare professionals to report suspected reactions through its Med Safety App, which is available for download on Android and iOS devices, or at the nearest NAFDAC office.
“Members of the public and healthcare professionals are encouraged to report suspected adverse drug reactions through the NAFDAC Med Safety App, available for download on Android and iOS devices, or at the nearest NAFDAC office,” the statement read.
NAFDAC also urged Nigerians to stop spreading the claim, particularly on social media, warning against the circulation of unverified information about the medicine.
“NAFDAC urges the public to stop circulating the false claim. Those who have already shared it are encouraged to disseminate this clarification through the same channels to help counter misinformation and prevent unnecessary public concern,” it stated.
The agency’s clarification comes amid the circulation of social media claims alleging that Camosunate had been banned in Nigeria because of reported adverse effects.
